Onconetix Completes 1-for-5 Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

Onconetix formally completed its 1-for-5 reverse stock split, effective March 25, 2026, to maintain Nasdaq listing compliance, reducing outstanding shares and increasing the potential for future dilution.

check_boxKey Events · Corporate Governance and Compliance · ONCO

• Reverse Stock Split Effective

  The 1-for-5 reverse stock split became effective at 12:01 a.m. Eastern Time on March 25, 2026, with shares trading on a split-adjusted basis since market open on that date.

• Nasdaq Listing Compliance

  The reverse stock split was implemented to enable the company to maintain compliance with The Nasdaq Capital Market's minimum bid price requirement.

• Share Count Reduction

  The reverse split reduced the number of issued and outstanding common shares from 3,464,686 to 692,927.

• Increased Dilution Potential

  There was no corresponding reduction in the number of authorized shares, which significantly increases the potential for future dilution relative to the reduced outstanding share count.

auto_awesomeAnalysis · ONCO · Life Sciences

Onconetix has formally completed its 1-for-5 reverse stock split, a critical action to maintain compliance with Nasdaq's minimum bid price requirement. This follows the company's recent disclosure of substantial doubt about its ability to continue as a going concern and its pursuit of additional reverse stock split authority. While the reverse split addresses an immediate delisting threat, the fact that authorized shares were not proportionally reduced significantly increases the potential for future dilution, which is a negative implication for existing shareholders, especially given the company's pending highly dilutive merger.